Monoamine Oxidase as Potential Drug Target
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: closed (30 June 2023) | Viewed by 253
Special Issue Editors
Interests: monoamine oxidase; dopaminergic system; movement disorders
Special Issue Information
Dear Colleagues,
Monoamine oxidase (MAO) is an enzyme involved in the metabolism of monoamines. The improvement of mood symptoms in tuberculosis patients taking iproniazid in the 1950s stimulated the search for new pharmacological agents with MAO inhibitor activity. The functional characterization of two isoforms of MAO, since MAO-A and MAO-B are distinguished by different substrate specificity and inhibitor sensitivity, leads to the search for drugs that selectively inhibit each isoform of MAO. The inhibition of MAO-A is associated with the improvement of mood symptoms, while MAO-B is a target of drugs with antiparkinsonian effects. Today, MAO has been the pharmacological drug target due to its involvement in other neurodegenerative diseases beyond Parkinson’s disease appearing upregulated in some age-associated pathologies. The modulation of MAO activity can lead to the overproduction of reactive oxygen species such as H2O2 and consequent activation of downstream signaling pathways associated with neuronal damage in neurodegenerative diseases. Since MAO inhibitors are associated with side effects, the search for new pharmacological agents, either natural or synthetic, on MAO isoforms as a target and favorable pharmacological profile is necessary. This Special Issue aims to publish original articles about MAO as a potential drug target. The collection of manuscripts will be published as a Special Issue of the journal.
Prof. Dr. Roselei Fachinetto
Dr. Nilda De Vargas Barbosa
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- MAO activity
- MAO inhibitors
- natural compounds
- drug repositioning
- preclinical and in vitro studies
- oxidative stress
- mood disorders
- neurodegenerative diseases
